Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MnTBAP chloride (Mn(III)TBAP) 是一种具有细胞渗透性的超氧化物歧化酶 (SOD) 模拟物和过氧亚硝酸盐清除剂,能使SOD-大肠杆菌的加倍时间减少了2倍。 MnTBAP chloride 通过上调 BMPR-II 和抑制 NFκB 信号传导展现抗炎作用。MnTBAP chloride 是一种锰卟啉配合物,具有抗氧化性能,具有用于研究慢性肾脏疾病 (CKDs) 纤维化反应的潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 248 | 现货 | ||
10 mg | ¥ 355 | 现货 | ||
25 mg | ¥ 578 | 现货 | ||
50 mg | ¥ 990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | MnTBAP chloride (Mn(III)TBAP) is a cell-permeable superoxide dismutase (SOD) mimetic and peroxynitrite scavenger that reduces the doubling time of SOD-E. coli by a factor of 2. MnTBAP chloride exhibits anti-inflammatory effects through upregulation of BMPR-II and inhibition of NFκB signaling. mnTBAP chloride is a manganese porphyrin complex with antioxidant properties and has potential for use in the study of fibrotic responses in chronic kidney diseases (CKDs). |
体外活性 | Due to its superoxide dismutase mimetic property, 50 microM MnTBAP was found to attenuate the injury produced dose-dependently by exposure to various concentrations of paraquat for 4 h. MnTBAP also protected endothelial cells in a dose-dependent manner against paraquat. The protective effect of MnTBAP appears to be caused by its intracellular superoxide-scavenging activity because neither the zinc form nor CuZnSOD protected the cells against paraquat-induced injury.[1] |
体内活性 | Local administration of MnTBAP significantly and reduced carrageenan-induced paw oedema dose-dependently at all time points, which was related to its superoxide dismutase mimetic property. MnTBAP also caused a significant dose-dependent reduction in paw myeloperoxidase activity, as well as preventing histological injury. Immunohistochemical analyses for nitrotyrosine showed a positive staining in paw from carrageenan-treated rats.[2] |
别名 | Mn(III)TBAP |
分子量 | 876.13 |
分子式 | C48H25ClMnN4O8 |
CAS No. | 55266-18-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (102.4 mM), Sonication is recommended.
0.5 M NaOH: 18.0 mg/mL (20.5 mM), Sonication is recommended.
1M NaOH: 9.0 mg/mL (10.2 mM), when pH is adjusted to 8 with NaOH. Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / 0.5 M NaOH / 1M NaOH | 1 mM | 1.1414 mL | 5.7069 mL | 11.4138 mL | 28.5346 mL |
5 mM | 0.2283 mL | 1.1414 mL | 2.2828 mL | 5.7069 mL | |
10 mM | 0.1141 mL | 0.5707 mL | 1.1414 mL | 2.8535 mL | |
DMSO / 0.5 M NaOH | 20 mM | 0.0571 mL | 0.2853 mL | 0.5707 mL | 1.4267 mL |
DMSO | 50 mM | 0.0228 mL | 0.1141 mL | 0.2283 mL | 0.5707 mL |
100 mM | 0.0114 mL | 0.0571 mL | 0.1141 mL | 0.2853 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MnTBAP chloride 55266-18-7 Mn(III)TBAP MnTBAP Chloride Inhibitor inhibitor inhibit